Download Image
    
Share
  
Post
Danicopan for COVID-19
1 study with 201 patients
Hospital Icon Control
Hospital Icon Danicopan Serious Outcome Risk
COVID-19 Danicopan studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -43% Mortality -43% Hospitalization -19% RCTs -43% Late -43% Favorsdanicopan Favorscontrol
Apr 23
2022
 Beigel et al., NCT04988035 ACTIV-5 /​ Big Effect Trial (BET-C) for the Treatment of COVID-19
43% higher mortality (p=0.34), 17% higher ventilation (p=0.69), 54% worse recovery (p=0.01), and 37% worse improvement (p=0.06). RCT 201 hospitalized COVID-19 patients showing increased risk with danicopan treatment, with statistical significance for time to sustained recovery.